Skip to content
Clinical Trials – home

Botulinum Toxin Type A - Haemagglutinin Complex: A Comprehensive Guide for Patients

11 / 16
trials open to patients / all trials
13+
Countries

In short

This article summarizes several clinical trials investigating the use of Botulinum Toxin Type A - Haemagglutinin Complex (commonly known as Botox or Dysport) for treating various medical conditions. The trials explore its efficacy and safety for chronic and episodic migraines, upper limb spasticity, facial lines, arm tremors in dystonia patients, and spastic equinovarus in stroke patients. These studies aim to optimize treatment protocols and better understand how this versatile drug works for different conditions.

What is Botulinum Toxin Type A?

Botulinum Toxin Type A - Haemagglutinin Complex, also known as abobotulinumtoxinA, is a medical treatment derived from the bacterium Clostridium botulinum. It's commonly referred to by brand names such as Dysport® or Azzalure®. This treatment is part of a class of medications called neurotoxins, which work by temporarily blocking nerve signals in specific areas of the body.

Medical Conditions Treated

Botulinum Toxin Type A is used to treat various medical conditions, including:

  • Chronic migraine: For adults experiencing 15 or more headache days per month, with at least 8 being migraines
  • Episodic migraine: For adults with 6-14 migraine days per month
  • Upper limb spasticity: Muscle stiffness and tightness in the arm, often following a stroke
  • Spastic equinovarus: A condition causing foot and ankle deformity in stroke patients
  • Dystonic tremor syndrome: Involuntary muscle contractions causing tremors
  • Moderate to severe upper facial lines: Including glabellar (frown) lines, forehead lines, and lateral canthal lines (crow's feet)

How It Works

Botulinum Toxin Type A works by temporarily blocking the nerve signals that cause muscle contractions. When injected into specific muscles, it reduces their activity, which can help alleviate symptoms in various conditions. For example, in migraines, it's believed to work by blocking pain signals and reducing muscle tension that may contribute to headaches.

How It's Administered

The treatment is administered through injections directly into the affected muscles. The specific injection sites and doses vary depending on the condition being treated. For instance:

  • For chronic migraine, injections are typically given in multiple sites around the head and neck
  • For upper limb spasticity, injections target specific muscles in the arm
  • For facial lines, injections are made into the muscles responsible for creating wrinkles

The procedure is usually performed in a doctor's office and takes about 10-15 minutes. Most patients describe the injections as feeling like small pinches.

Efficacy

Clinical trials have shown Botulinum Toxin Type A to be effective for its approved uses:

  • For chronic migraine, it can significantly reduce the number of headache days per month
  • In upper limb spasticity, it can improve muscle tone and function
  • For facial lines, it can provide noticeable improvement in the appearance of wrinkles

However, individual responses can vary, and it may take several days to a few weeks to see the full effects of the treatment.

Safety and Side Effects

Botulinum Toxin Type A is generally considered safe when administered by a qualified healthcare professional. However, like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions (pain, swelling, redness)
  • Headache
  • Muscle weakness near the injection site
  • Drooping eyelids (when used for facial treatments)

Serious side effects are rare but can include difficulty swallowing or breathing. It's important to report any unusual symptoms to your healthcare provider immediately.

Duration of Effects

The effects of Botulinum Toxin Type A are temporary. Depending on the condition being treated, the effects typically last 3-6 months. For example:

  • For chronic migraine, treatments are usually given every 12 weeks
  • For facial lines, effects may last up to 4 months

After the effects wear off, repeat treatments are necessary to maintain the benefits.

Important Considerations

Before receiving Botulinum Toxin Type A treatment, it's important to:

  • Inform your doctor about all medications you're taking, especially those that affect muscle function or blood clotting
  • Disclose any history of neuromuscular disorders
  • Avoid alcohol and blood-thinning medications for a few days before treatment
  • Be aware that pregnancy and breastfeeding are typically contraindications for this treatment

Remember, Botulinum Toxin Type A should only be administered by qualified healthcare professionals in appropriate medical settings. Always follow your doctor's instructions for the best and safest results.

Questions people often ask

Conditions where Botulinum Toxin Type A - Haemagglutinin Complex is being studied

Each condition opens its own overview and trial list

Trials with Botulinum Toxin Type A - Haemagglutinin Complex

Recruiting trials first

See all 16 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).